Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab (PK-rituximab)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00820469|
Recruitment Status : Completed
First Posted : January 12, 2009
Last Update Posted : May 12, 2017
Rituximab (a monoclonal antibody raised against CD20) is used to treat various immune disorders. In some cases such as treatment of humoral acute rejection of renal transplant, thrombotic thrombocytopenic purpura, vasculitis or cryoglobulinemia, rituximab is often associated with plasma exchange. The pharmacokinetic of the rituximab can be affected by plasma exchange but the knowledge is poor in this matter.
The aim of the study is to explore the influence of plasma exchange on the pharmacokinetic of rituximab.
The results of this study should conclude if plasma exchange leads to a significant decrease of plasma concentration of rituximab or not, and if the decreased of the concentration is associated with a decrease in efficacy.
|Condition or disease||Intervention/treatment||Phase|
|Renal Transplant Autoimmune Diseases||Drug: Rituximab 375 Drug: rituximab 1000||Phase 4|
Twenty patients will be enrolled: ten patients treated by rituximab and ten patients treated by rituximab and plasma exchange. The plasma concentration of rituximab and the efficacy of the treatment will be compared between the two groups of patients.
The enrollment in the study will not change the treatment of patients except for blood sampling.
Each patient will undergo fifteen blood samples between the start of infusion of rituximab and three months after the start of infusion. For the patients who will undergo plasma exchange, three additional blood samples will be performed at each plasma exchange (at the start, at the end and one day after the plasma exchange) and a sample of the plasma exchanged will be keep.
The plasma concentration of rituximab will be determined by ELISA method (Enzyme Linked ImmunoSorbent Assay) The pharmacokinetic analyse will consist in the determination of the Area Under the Concentration Curve (AUC) by a non compartmental approach.
The AUC levels will be compared (using the t Student test) between the two populations of patients (patients treated by rituximab, versus patients treated by rituximab and plasma exchange) The efficacy of the treatment will be evaluated by the CD19+ B Cell count.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Influence of Plasma Exchange Therapy on the Pharmacokinetics of Rituximab in Patients Treated for Autoimmune Disorders.|
|Study Start Date :||September 2008|
|Actual Primary Completion Date :||November 2009|
|Actual Study Completion Date :||January 2010|
Patients treated by rituximab
Drug: Rituximab 375
rituximab 375 mg/m2 IV weekly, during 4 weeks
Patients treated by rituximab and plasma exchange
Drug: rituximab 1000
rituximab 1000 mg IV, two infusions on day 1 and day 15
- Comparison of the total AUC levels between 2 arms : patients treated by rituximab alone or patients treated by rituximab and plasma exchange [ Time Frame: Determination on the overall plasma concentration profile between the start of infusion and three months after the start of infusion ]
- Determination of amount rituximab eliminated during a plasma exchange [ Time Frame: At each plasma exchange ]
- Evaluation of the efficacy of the treatment by CD19+B Cell count [ Time Frame: 15 dyas, 1, 2, 3, 6 and 9 months after rituximab infusion ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00820469
|University Hospital Toulouse|
|Toulouse, France, 31000|
|Principal Investigator:||Jacques Pourrat, MD||University Hospital, Toulouse|